Involvement of the primate specific gene G72 in schizophrenia: From genetic studies to pathomechanisms

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2410-2417

  Drews, Eva ^a   Otte, David Marian ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

G72 transgenic mice; Mitochondrial dysfunctions; Oxidative stress; Psychiatric disorders

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; DEXTRO AMINO ACID OXIDASE; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN LG72; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN REGION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC TRANSMISSION; G72 GENE; G72 TRANSGENIC MOUSE; GENE; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; TRANSGENIC MOUSE;

G72 TRANSGENIC MICE; MITOCHONDRIAL DYSFUNCTIONS; OXIDATIVE STRESS; PSYCHIATRIC DISORDERS;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CARRIER PROTEINS; ELECTRON TRANSPORT COMPLEX I; HUMANS; MICE; MICE, TRANSGENIC; MITOCHONDRIAL DISEASES; NEURONAL PLASTICITY; SCHIZOPHRENIA;

EID: 84890224606     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.10.009     Document Type: Review

References (89)

1. Abou Jamra R., Schmael C., Cichon S., Rietschel M., Schumacher J., Nothen M.M. The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries?. Schizophrenia Bulletin 2006, 32:599-608.
2. Akshoomoff N.A., Courchesne E. A new role for the cerebellum in cognitive operations. Behavioral Neuroscience 1992, 106:731-738.
3. Altar C.A., Jurata L.W., Charles V., Lemire A., Liu P., Bukhman Y., Young T.A., Bullard J., Yokoe H., Webster M.J., et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biological Psychiatry 2005, 58:85-96.
4. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Research Bulletin 2010, 83:147-161.
5. Andreasen N.C., Pierson R. The role of the cerebellum in schizophrenia. Biological Psychiatry 2008, 64:81-88.
6. Andreou D., Saetre P., Werge T., Andreassen O.A., Agartz I., Sedvall G.C., Hall H., Terenius L., Jonsson E.G. d-Amino acid oxidase activator gene (DAOA) variation affects cerebrospinal fluid homovanillic acid concentrations in healthy Caucasians. European Archives of Psychiatry and Clinical Neuroscience 2012.
7. Atanasova B., Graux J., El Hage W., Hommet C., Camus V., Belzung C. Olfaction: a potential cognitive marker of psychiatric disorders. Neuroscience and Biobehavioral Reviews 2008, 32:1315-1325.
8. Barch D.M. The cognitive neuroscience of schizophrenia. Annual Review of Clinical Psychology 2005, 1:321-353.
9. Bass N.J., Datta S.R., McQuillin A., Puri V., Choudhury K., Thirumalai S., Lawrence J., Quested D., Pimm J., Curtis D., et al. Evidence for the association of the DAOA (G72) gene with schizophrenia and bipolar disorder but not for the association of the DAO gene with schizophrenia. Behavioral and Brain Functions 2009, 5:28.
10. Bellebaum C., Daum I. Cerebellar involvement in executive control. Cerebellum 2007, 6:184-192.
11. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophrenia Research 2007, 90:41-51.
12. Bergen S.E., Petryshen T.L. Genome-wide association studies of schizophrenia: does bigger lead to better results?. Current Opinion in Psychiatry 2012, 25:76-82.
13. Brewer W.J., Wood S.J., McGorry P.D., Francey S.M., Phillips L.J., Yung A.R., Anderson V., Copolov D.L., Singh B., Velakoulis D., et al. Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. American Journal of Psychiatry 2003, 160:1790-1794.
14. Bromet E.J., Fennig S. Epidemiology and natural history of schizophrenia. Biological Psychiatry 1999, 46:871-881.
15. Bubenikova-Valesova V., Horacek J., Vrajova M., Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neuroscience and Biobehavioral Reviews 2008, 32:1014-1023.
16. Campbell I.M., Gregson R.A.M. Olfactory short term memory in normal, schizophrenic and brain-damaged cases. Australian Journal of Psychology 1972, 24:179-185.
17. Chen J., Lipska B.K., Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biological Psychiatry 2006, 59:1180-1188.
18. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., et al. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:13675-13680.
19. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. International Journal of Developmental Neuroscience 2011, 29:311-324.
20. Corvin A., McGhee K.A., Murphy K., Donohoe G., Nangle J.M., Schwaiger S., Kenny N., Clarke S., Meagher D., Quinn J., et al. Evidence for association and epistasis at the DAOA/G30 and d-amino acid oxidase loci in an Irish schizophrenia sample. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2007, 144B:949-953.
21. Courchesne E., Akshoomoff N.A., Townsend J., Saitoh O. A model system for the study of attention and the cerebellum: infantile autism. Electroencephalography and Clinical Neurophysiology: Supplement 1995, 44:315-325.
22. Courchesne E., Townsend J., Akshoomoff N.A., Saitoh O., Yeung-Courchesne R., Lincoln A.J., James H.E., Haas R.H., Schreibman L., Lau L. Impairment in shifting attention in autistic and cerebellar patients. Behavioral Neuroscience 1994, 108:848-865.
23. de Greef R., Maloney A., Olsson-Gisleskog P., Schoemaker J., Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS Journal 2011, 13:121-130.
24. Detera-Wadleigh S.D., McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biological Psychiatry 2006, 60:106-114.
25. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. The European Journal of Neuroscience 2000, 12:3721-3728.
26. Field J.R., Walker A.G., Conn P.J. Targeting glutamate synapses in schizophrenia. Trends in Molecular Medicine 2011, 17:689-698.
27. Gao J.H., Parsons L.M., Bower J.M., Xiong J., Li J., Fox P.T. Cerebellum implicated in sensory acquisition and discrimination rather than motor control. Science 1996, 272:545-547.
28. Gejman P.V., Sanders A.R., Kendler K.S. Genetics of schizophrenia: new findings and challenges. Annual Review of Genomics and Human Genetics 2011, 12:121-144.
29. Geyer M.A., McIlwain K.L., Paylor R. Mouse genetic models for prepulse inhibition: an early review. Molecular Psychiatry 2002, 7:1039-1053.
30. Gruber O. Effects of domain-specific interference on brain activation associated with verbal working memory task performance. Cerebral Cortex 2001, 11:1047-1055.
31. Gruber O., Karch S., Schlueter E.K., Falkai P., Goschke T. Neural mechanisms of advance preparation in task switching. Neuroimage 2006, 31:887-895.
32. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., Deppen P., Preisig M., Ruiz V., Steullet P., et al. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16621-16626.
33. Haarmeier T., Thier P. The attentive cerebellum-myth or reality?. Cerebellum 2007, 6:177-183.
34. Hartz S.M., Ho B.C., Andreasen N.C., Librant A., Rudd D., Epping E.A., Wassink T.H. G72 influences longitudinal change in frontal lobe volume in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2010, 153B:640-647.
35. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:767-769.
36. Heckers S., Konradi C. Hippocampal pathology in schizophrenia. Current Topics in Behavioral Neurosciences 2010, 4:529-553.
37. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
38. Ishizuka K., Paek M., Kamiya A., Sawa A. A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biological Psychiatry 2006, 59:1189-1197.
39. James A.M., Smith R.A., Murphy M.P. Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Archives of Biochemistry and Biophysics 2004, 423:47-56.
40. Jonsson E.G., Saetre P., Vares M., Andreou D., Larsson K., Timm S., Rasmussen H.B., Djurovic S., Melle I., Andreassen O.A., et al. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. Neuropsychobiology 2009, 59:142-150.
41. Kantrowitz J., Javitt D.C. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Current Opinion in Psychiatry 2012, 25:96-102.
42. Kantrowitz J.T., Malhotra A.K., Cornblatt B., Silipo G., Balla A., Suckow R.F., D'Souza C., Saksa J., Woods S.W., Javitt D.C. High dose d-serine in the treatment of schizophrenia. Schizophrenia Research 2010, 121:125-130.
43. Kato T., Kuratomi G., Kato N. Genetics of bipolar disorder. Drugs Today (Barc) 2005, 41:335-344.
44. Kawazoe T., Park H.K., Iwana S., Tsuge H., Fukui K. Human d-amino acid oxidase: an update and review. Chemical Record 2007, 7:305-315.
45. Kim B., Kim H., Joo Y.H., Lim J., Kim C.Y., Song K. Sex-different association of DAO with schizophrenia in Koreans. Psychiatry Research 2010, 179:121-125.
46. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters 1980, 20:379-382.
47. Kvajo M., Dhilla A., Swor D.E., Karayiorgou M., Gogos J.A. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Molecular Psychiatry 2008, 13:685-696.
48. Kwapil T.R., Chapman J.P., Chapman L.J., Miller M.B. Deviant olfactory experiences as indicators of risk for psychosis. Schizophrenia Bulletin 1996, 22:371-382.
49. Labrie V., Wong A.H., Roder J.C. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology 2012, 62:1484-1503.
50. Lang U.E., Puls I., Muller D.J., Strutz-Seebohm N., Gallinat J. Molecular mechanisms of schizophrenia. Cellular Physiology and Biochemistry 2007, 20:687-702.
51. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
52. Lin C.H., Lane H.Y., Tsai G.E. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology Biochemistry and Behavior 2012, 100:665-677.
53. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends in Pharmacological Sciences 2011, 32:507-513.
54. Madeira C., Freitas M.E., Vargas-Lopes C., Wolosker H., Panizzutti R. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophrenia Research 2008, 101:76-83.
55. Martin A., Haxby J.V., Lalonde F.M., Wiggs C.L., Ungerleider L.G. Discrete cortical regions associated with knowledge of color and knowledge of action. Science 1995, 270:102-105.
56. McGrath J., Scott J. Urban birth and risk of schizophrenia: a worrying example of epidemiology where the data are stronger than the hypotheses. Epidemiologia e Psichiatria Sociale 2006, 15:243-246.
57. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Current Medical Research and Opinion 1997, 14:1-20.
58. Meyer U., Feldon J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 2009, 206:587-602.
59. Millar J.K., James R., Christie S., Porteous D.J. Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria. Molecular and Cellular Neurosciences 2005, 30:477-484.
60. Miyamoto S., LaMantia A.S., Duncan G.E., Sullivan P., Gilmore J.H., Lieberman J.A. Recent advances in the neurobiology of schizophrenia. Molecular Interventions 2003, 3:27-39.
61. Molinari M., Leggio M.G. Cerebellar information processing and visuospatial functions. Cerebellum 2007, 6:214-220.
62. Molla G., Sacchi S., Bernasconi M., Pilone M.S., Fukui K., Polegioni L. Characterization of human d-amino acid oxidase. FEBS Letters 2006, 580:2358-2364.
63. Mossner R., Schuhmacher A., Wagner M., Quednow B.B., Frommann I., Kuhn K.U., Schwab S.G., Rietschel M., Falkai P., Wolwer W., et al. DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience 2010, 260:209-215.
64. Muller D.J., Zai C.C., Shinkai T., Strauss J., Kennedy J.L. Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. Bipolar Disorders 2011, 13:198-207.
65. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nature Neuroscience 2010, 13:1161-1169.
66. Newman-Tancredi A., Kleven M.S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 2011, 216:451-473.
67. Ohi K., Hashimoto R., Yasuda Y., Yoshida T., Takahashi H., Iike N., Fukumoto M., Takamura H., Iwase M., Kamino K., et al. Association study of the G72 gene with schizophrenia in a Japanese population: a multicenter study. Schizophrenia Research 2009, 109:80-85.
68. Otte D.M., Bilkei-Gorzo A., Filiou M.D., Turck C.W., Yilmaz O., Holst M.I., Schilling K., Abou-Jamra R., Schumacher J., Benzel I., et al. Behavioral changes in G72/G30 transgenic mice. European Neuropsychopharmacology 2009, 19:339-348.
69. Otte D.M., Sommersberg B., Kudin A., Guerrero C., Albayram O., Filiou M.D., Frisch P., Yilmaz O., Drews E., Turck C.W., et al. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology 2011, 36:2233-2243.
70. Pollegioni L., Piubelli L., Sacchi S., Pilone M.S., Molla G. Physiological functions of d-amino acid oxidases: from yeast to humans. Cellular and Molecular Life Sciences 2007, 64:1373-1394.
71. Rezin G.T., Amboni G., Zugno A.I., Quevedo J., Streck E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochemical Research 2009, 34:1021-1029.
72. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., et al. Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 2011, 43:969-976.
73. Rubino T., Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Molecular and Cellular Endocrinology 2008, 286:S108-S113.
74. Rupp C.I. Olfactory function and schizophrenia: an update. Current Opinion in Psychiatry 2010, 23:97-102.
75. Sacchi S., Bernasconi M., Martineau M., Mothet J.P., Ruzzene M., Pilone M.S., Pollegioni L., Molla G. pLG72 modulates intracellular d-serine levels through its interaction with d-amino acid oxidase: effect on schizophrenia susceptibility. Journal of Biological Chemistry 2008, 283:22244-22256.
76. Sacchi S., Cappelletti P., Giovannardi S., Pollegioni L. Evidence for the interaction of d-amino acid oxidase with pLG72 in a glial cell line. Molecular and Cellular Neurosciences 2011, 48:20-28.
77. Salin P.A., Scanziani M., Malenka R.C., Nicoll R.A. Distinct short-term plasticity at two excitatory synapses in the hippocampus. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13304-13309.
78. Schultz C.C., Nenadic I., Koch K., Wagner G., Roebel M., Schachtzabel C., Muhleisen T.W., Nothen M.M., Cichon S., Deufel T., et al. Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia. Neuropsychopharmacology 2011, 36:1747-1753.
79. Sivrioglu E.Y., Kirli S., Sipahioglu D., Gursoy B., Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:1493-1499.
80. Smith J.W., Gastambide F., Gilmour G., Dix S., Foss J., Lloyd K., Malik N., Tricklebank M. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology 2011, 217:255-269.
81. Steffek A.E., Haroutunian V., Meador-Woodruff J.H. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport 2006, 17:1181-1185.
82. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008, 199:331-388.
83. Tsuang M. Schizophrenia: genes and environment. Biological Psychiatry 2000, 47:210-220.
84. Turetsky B.I., Hahn C.G., Borgmann-Winter K., Moberg P.J. Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophrenia Bulletin 2009, 35:1117-1131.
85. van Os J., Kapur S. Schizophrenia. The Lancet 2009, 374:635-645.
86. van Os J., Krabbendam L., Myin-Germeys I., Delespaul P. The schizophrenia envirome. Current Opinion in Psychiatry 2005, 18:141-145.
87. Verrall L., Burnet P.W., Betts J.F., Harrison P.J. The neurobiology of d-amino acid oxidase and its involvement in schizophrenia. Molecular Psychiatry 2010, 15:122-137.
88. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006, 81:291-300.
89. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., Kosten T.A., Kosten T.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. The Journal of Clinical Psychiatry 2007, 68:754-760.